The enzymatic activity of CYP1A2 and CYP2C19 were increased with the progressing NAFLD, while the activity of CYP2A6, and CYP2C9 were found increased with NAFLD severity with different drugs metabolism. This evidence concerns the gene CYP1A2 and metabolic dysfunction-associated steatotic liver disease.